FDA accepted for review Samsung Bioepis’ BLA for SB2, a biosimilar to Remicade (infliximab).
FDA has accepted for review Samsung Bioepis’ Biologics License Application (BLA) for SB2, a biosimilar candidate referencing Remicade (infliximab), for the treatment of rheumatoid arthritis, Crohn’s disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, and psoriasis. According to a May 24, 2016 press announcement, this is the first Samsung Bioepis biosimilar candidate submitted for review in the United States. If approved, Merck will handle the marketing and distribution of SB2 in the US.
If FDA gives the green light to SB2, it will be the second mAb biosimilar (and second Remicade biosimilar) to hit the US market. Celltrion and Pfizer’s Remicade biosimilar Inflectra (infliximab) was approved by FDA on April 5, 2016. Inflectra is the first monoclonal antibody (mAb)-based biosimilar to be approved in the US. The drug was approved for all of Remicade’s indications except pediatric ulcerative colitis, which is still covered by orphan drug exclusivity until September 23, 2018.
In early April 2016, Samsung Bioepis received a positive recommendation from the Committee for Medicinal Products for Human Use (CHMP) for its Remicade biosimilar Flixabi (infliximab) in Europe. If granted marketing authorization, Biogen will commercialize the drug in the European Union. Samsung Bioepis currently has 13 biosimilar candidates in its pipeline, including drugs referencing etanercept, adalimumab, insulin glargine, trastuzumab, and bevacizumab.
Source: Samsung Bioepis
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
VERAXA and Voyager to Create Combined Business for Advancing Pipeline of Next-Gen Cancer Therapies
April 23rd 2025The proposed business combination would create a publicly traded, clinical-stage biopharmaceutical company that will focus on developing a pipeline of next-generation cancer therapies.